Meditation brain study in Parkinson's withdrawn before starting
NCT ID NCT05103618
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study planned to use brain scans to measure how a meditation technique called OM affects dopamine and stress markers in people with Parkinson's disease. It was withdrawn before enrolling any participants, so no results are available. The goal was to better understand meditation's potential impact on brain health in Parkinson's.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- OM Meditation (behavioral) and [F-18] Fluorodopa (imaging tracer)
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Thomas Jefferson University, Marcus Institute of Integrative Health Centers
Philadelphia, Pennsylvania, 19107, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Planning ahead: could a simple program transform Parkinson's care?
- Sound waves vs. Parkinson's: can ultrasound calm tremors and stiffness?
- Can a nudge in your chart unlock Life-Saving genetic clues?
- Can MRI reveal the Brain's response to deep brain stimulation?
- Can we outsmart Gaucher's hidden toll on lungs, bones, and brain?
- Could a brain disease change behavior years before diagnosis?